Oxandrin tablets

Warfarin : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from to ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. Microscopic hematuria (9/15) and gingival bleeding (1/15) were also observed. A -fold decrease in the mean warfarin dose from mg/day to mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of . When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.

Oxandrin tablets

oxandrin tablets


oxandrin tabletsoxandrin tabletsoxandrin tabletsoxandrin tabletsoxandrin tablets